Literature DB >> 14651729

Free and bound propofol concentrations in human cerebrospinal fluid.

Andrzej L Dawidowicz1, Rafal Kalitynski, Anna Fijalkowska.   

Abstract

AIMS: The aim of this study was to define the relationship between unbound propofol concentrations in plasma and total drug concentrations in human cerebrospinal fluid (CSF), and to determine whether propofol exists in the CSF in bound form.
METHODS: Forty-three patients (divided into three groups) scheduled for elective intracranial procedures and anaesthetized by propofol target control infusion (TCI) were studied. Blood and CSF samples (taken from the radial artery, and the intraventricular drainage, respectively) from group I (17 patients) were used to investigate the relationship between unbound propofol concentration in plasma and total concentration of the drug in CSF. CSF samples taken from group II (18 patients) were used to confirm the presence of the bound form of propofol in this fluid. The CSF and blood samples taken from group III (eight patients) were used to monitor the course of free and bound CSF propofol concentrations during anaesthesia.
RESULTS: For group I patients the mean (and 95% confidence interval) total plasma propofol concentration was 6113 (4971, 7255) ng ml(-1), the mean free propofol concentration in plasma was 63 (42, 84) ng ml(-1), and the mean total propofol concentration in CSF was 96 (76, 116) ng ml(-1) (P < 0.05 for the difference between the last two values). For group II patients the fraction of free propofol in CSF was 31 (26, 37)%. For group III patients the fraction of free propofol in CSF during TCI was almost constant (about 36%).
CONCLUSIONS: The unbound propofol concentration in plasma was not equal to its total concentration in CSF and cannot be directly related to the drug concentration in the brain. Binding of propofol to components of the CSF may be an additional mechanism regulating the transport of the drug from blood into CSF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14651729      PMCID: PMC1884396          DOI: 10.1046/j.1365-2125.2003.01920.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Investigation of propofol renal elimination by HPLC using supported liquid membrane procedure for sample preparation.

Authors:  Andrzej L Dawidowicz; Rafał Kalityński; Jerzy Trocewicz; Andrzej Nestorowicz; Anna Fijałkowska; Katarzyna Trela-Stachurska
Journal:  Biomed Chromatogr       Date:  2002-10       Impact factor: 1.902

2.  Pharmacokinetics of propofol when given by intravenous infusion.

Authors:  D J Morgan; G A Campbell; D P Crankshaw
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

3.  Cerebrospinal fluid and blood propofol concentration during total intravenous anaesthesia for neurosurgery.

Authors:  A L Dawidowicz; A Fijałkowska; A Nestorowicz; R Kalityński; T Trojanowski
Journal:  Br J Anaesth       Date:  2003-01       Impact factor: 9.166

4.  Pharmacokinetic model selection for target controlled infusions of propofol. Assessment of three parameter sets.

Authors:  J F Coetzee; J B Glen; C A Wium; L Boshoff
Journal:  Anesthesiology       Date:  1995-06       Impact factor: 7.892

5.  Pharmacodynamics of propofol and free drug concentrations.

Authors:  T Gin
Journal:  Anesthesiology       Date:  1993-03       Impact factor: 7.892

Review 6.  Brain drug delivery, drug metabolism, and multidrug resistance at the choroid plexus.

Authors:  J F Ghersi-Egea; N Strazielle
Journal:  Microsc Res Tech       Date:  2001-01-01       Impact factor: 2.769

Review 7.  Propofol, the newest induction agent of anesthesia.

Authors:  J H Kanto
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1988-01

8.  Pharmacodynamics of propofol in female patients.

Authors:  J Vuyk; F H Engbers; H J Lemmens; A G Burm; A A Vletter; M P Gladines; J G Bovill
Journal:  Anesthesiology       Date:  1992-07       Impact factor: 7.892

Review 9.  Propofol. A review of its pharmacodynamic and pharmacokinetic properties and use as an intravenous anaesthetic.

Authors:  M S Langley; R C Heel
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

10.  Pharmacokinetics, pharmacodynamics, and rational opioid selection.

Authors:  S L Shafer; J R Varvel
Journal:  Anesthesiology       Date:  1991-01       Impact factor: 7.892

View more
  9 in total

1.  Age progression from vicenarians (20-29 year) to nonagenarians (90-99 year) among a population pharmacokinetic/pharmacodynamic (PopPk-PD) covariate analysis of propofol-bispectral index (BIS) electroencephalography.

Authors:  Ashraf A Dahaba; Zhaoyang Xiao; Xiaoling Zhu; Hailong Dong; Lize Xiong; Peter Rehak; Sieglinde Zelzer; Kun Wang; Gilbert Reibnegger
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-02-25       Impact factor: 2.745

2.  Cerebrospinal fluid and plasma propofol concentration during total intravenous anaesthesia of patients undergoing elective intracranial tumor removal.

Authors:  Wei Luo; Yu-Hong Li; Jian-Jun Yang; Jie Tian; Jian-Guo Xu
Journal:  J Zhejiang Univ Sci B       Date:  2005-09       Impact factor: 3.066

3.  Ionic mechanisms underlying the negative chronotropic action of propofol on sinoatrial node automaticity in guinea pig heart.

Authors:  Akiko Kojima; Yuki Ito; Hirotoshi Kitagawa; Hiroshi Matsuura
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

4.  Sleep Homeostasis and General Anesthesia: Are Fruit Flies Well Rested after Emergence from Propofol?

Authors:  Benjamin Gardner; Ewa Strus; Qing Cheng Meng; Thomas Coradetti; Nirinjini N Naidoo; Max B Kelz; Julie A Williams
Journal:  Anesthesiology       Date:  2016-02       Impact factor: 7.892

5.  Development of a highly sensitive gas chromatography-mass spectrometry method preceded by solid-phase microextraction for the analysis of propofol in low-volume cerebral microdialysate samples.

Authors:  Armin Sebastian Guntner; Simon Stöcklegger; Michael Kneidinger; Udo Illievich; Wolfgang Buchberger
Journal:  J Sep Sci       Date:  2019-01-30       Impact factor: 3.645

6.  Modulation of TRPC5 cation channels by halothane, chloroform and propofol.

Authors:  Y M Bahnasi; H M Wright; C J Milligan; A M Dedman; F Zeng; P M Hopkins; A N Bateson; D J Beech
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

Review 7.  Metabolic Profiles of Propofol and Fospropofol: Clinical and Forensic Interpretative Aspects.

Authors:  Ricardo Jorge Dinis-Oliveira
Journal:  Biomed Res Int       Date:  2018-05-24       Impact factor: 3.411

Review 8.  Clinical Pharmacokinetics and Pharmacodynamics of Propofol.

Authors:  Marko M Sahinovic; Michel M R F Struys; Anthony R Absalom
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

9.  Steady-state activation and modulation of the synaptic-type α1β2γ2L GABAA receptor by combinations of physiological and clinical ligands.

Authors:  Allison L Germann; Spencer R Pierce; Thomas C Senneff; Ariel B Burbridge; Joe Henry Steinbach; Gustav Akk
Journal:  Physiol Rep       Date:  2019-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.